Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IPX203
- Development stage
- Approved
- Lead developer
- Amneal Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
IPX203 (Crexont) is an oral extended-release formulation of carbidopa and levodopa developed by Amneal Pharmaceuticals and Zambon Biotech for the treatment of Parkinson's disease. It utilizes a multi-particulate delivery system consisting of immediate-release granules and polymer-coated extended-release beads, designed to provide a rapid onset of action and a significantly longer duration of 'ON' time compared to immediate-release carbidopa-levodopa. The FDA approved IPX203 under the brand name Crexont in August 2024 for the treatment of Parkinson's disease, including patients experiencing motor fluctuations. In Europe, Zambon Biotech is conducting Phase 3b trials (such as the ADIP study) to further evaluate its efficacy and safety in advanced Parkinson's disease patients.
- Brand names
- Crexont
- Other names
- carbidopa/levodopa extended-release capsules
02
Targets
DDC (Aromatic L-amino acid decarboxylase)DRD (Dopamine receptors)
Beyond the preview
Go deeper on IPX203.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IPX203.